Editorial
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hematol. Nov 12, 2018; 7(1): 1-3
Published online Nov 12, 2018. doi: 10.5315/wjh.v7.i1.1
miRNA and platelet genetic machinery
Pedro C Redondo
Pedro C Redondo, Department of Physiology, Institute of Molecular Pathology Biomarkers, University of Extremadura, Caceres 10003, Spain
ORCID number: Pedro C Redondo (0000-0002-2067-2627).
Author contributions: Redondo PC has written the manuscript.
Conflict-of-interest statement: Redondo PC declares no conflict of interest related to this publication.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author to: Pedro C Redondo, PhD, Academic Research, Professor, Department of Physiology, Institute of Molecular Pathology Biomarkers, University of Extremadura, Plaza de Caldereros, s/n., Caceres 10003, Spain. pcr@unex.es
Telephone: +34-927-257106 Fax: +34-927-257110
Received: June 29, 2018
Peer-review started: July 2, 2018
First decision: August 9, 2018
Revised: September 14, 2018
Accepted: November 2, 2018
Article in press: November 2, 2018
Published online: November 12, 2018

Abstract

Platelets are responsible for blood haemostasis. Although anucleate, a complete translational machinery has been found in platelets, which is responsible for new protein generation. Recently, the role of miRNAs in platelets has started to become apparent. In this editorial I highlight this topic in the hope that other scientists may be attracted to work in this area to aid a more complete understanding of protein regulation in platelets and its impact on platelet function.

Key Words: Platelets, Thrombosis, Platelet agonists, miRNA

Core tip: miRNAs have been recently identified as a mechanism for regulating protein content in several cell types including platelets. In fact, certain miRNAs have been recently associated with some platelet-related pathologies. Moreover, changes in the miRNAs expression profiles have been evidenced in platelet activated by certain agonists. So, future researches will be needed to provide more information regarding platelet miRNAs in order to be used as an alternative therapy to the nowadays antiplatelet drugs.



INTRODUCTION

Platelets, though anucleate, are the main cells involved in haemostasis, since they produce or store many molecules that are released once they are activated. Platelet activation results in blood clotting, mainly through the interconnection of two different processes: the extrinsic and intrinsic pathways of the coagulation mechanism. The resulting blood clot requires the generation of a fibrin net that, together with the spread platelets, avoids the loss of other blood cells from the damaged blood vessel.

The fact that platelets are derived from megakaryocyte fragmentation, together with the lack of positive 4’,6-diamidino-2-phenylindole staining, lead to the incorrect conclusion that platelets have a poor translational machinery[1,2]. Therefore, early papers claimed that these cells were unable to produce new proteins. However, more recent work has demonstrated changes in mRNA and proteins in mature platelets, even over short time periods, similar to those found in nucleated cells[3-5]. The discovery of platelet microparticles, circulating small fragments derived from platelets that contain important regulatory factors, has further increased interest in this area. Platelet derived microparticles have been proposed to play a role in the transport of mRNA to other cells[6]. miRNA associated with platelet microparticles has been proposed as a regulatory pathway, or crosstalk mechanism, between platelets and other surrounding cells, such as monocytes and endothelial cells[7-9].

Another important issue is the regulatory effect of miRNA on platelet physiology. Since their discovery in nematodes in 2000[10], these small DNA fragments, derived from non-coding segments of DNA, have been shown to be an important mechanism of gene regulation. Polymerase II generates long RNA transcripts (called primary RNA) that are cleaved by a protein complex known as a microprocessor (resulting from the association of RNase III and DGCR8). After primary RNA is transported to the cytosol of cells, it is further processed by RNase III, DICER and argonaute proteins. Finally, mature miRNAs associate with the complementary 3’ untranslated regions of the target RNA, which results in a decrease in target protein expression[11]. Interestingly, the inhibitory effect of the miRNA changes with time and it is specific to a particular tissue, so it is possible to find different functions of a particular miRNA depending of the tissue and the pathology investigated.

Nowadays, there is a robust body of evidence concerning the presence and relevance of miRNA in platelet function and platelet-associated pathologies. Some important investigations and results are described below.

During platelet synthesis and maturation, miRNA 125b appears to regulate the initial phases of megakaryocyte maturation by targeting the cyclin-dependent kinase inhibitor p19 INK4D[12]. Interestingly, a cluster of three miRNAs (miRNA 23a/27a/24 2) counteracts miRNA 125b in platelet maturation from in vitro cultured megakaryocytes[13].

miRNAs have also been reported to regulate the expression of proteins involved in the function of mature circulating platelets. For example, artificial downregulation of miRNA 126 in murine platelets leads to reduced ADAM9 and P2Y12 receptor expression[14]. Furthermore, in stored human platelets, miRNA 320c has recently been reported to regulate platelet function by impairing RAP1 activation. RAP1 is regulated by CalDAG-GEFI and is involved in membrane expression of integrins downstream of the activation of ITAM- and G-coupled receptors[15]. Additionally, stored platelets exhibit apoptotic-like events. In fact, as early as the third day of storage, these cells exhibit a reduction of antiapoptotic Bcl-XL that is associated with an increase in proapoptotic Bak. miRNA let-7b has a 3’-UTR binding region for the Bcl-xL gene, resulting in down-regulation of Bcl-XL expression, and during platelet storage this miRNA shows increased expression[16]. The latter may be a relevant field for future study since it may help to improve the survival time of haematopoietic cell precursors, so prolonging the availability and efficiency of transfusion.

It is worth mentioning that miRNA may affect protein expression over very short time periods. In a recent publication, the authors listed around 72 miRNAs that are overexpressed and bind to argonaute proteins, and around 30-40 that are silenced in response to the platelet physiological agonist, thrombin. miRNA 27b, which showed reduced expression upon thrombin stimulation, downregulated thrombospondin-1 activity. Thrombospondin-1 is an important protein that participates in the mechanism of angiogenesis regulated by platelets[17].

Finally, the role of miRNAs in the progression of certain illnesses has recently been revealed. For example, in patients suffering essential thrombocytosis, a pool of miRNAs were found to be altered (miR-9, miRNA 490 5p, miRNA 490 3p, miRNA 182, miRNA 34a, miRNA 196b, miRNA 34b*, miRNA 181a 2*). The alteration in these miRNAs, together with a set of mRNA (CAV2, LAPTM4B, TIMP1, PKIG, WASF1, MMP1, ERVH-4, NME4, HSD17B12) and certain point mutations at the gene level, facilitates the progression of this chronic myeloproliferative disorder that leads to elevated platelet production, which may result in stroke, heart attack and the formation of blood clots in patients[18]. In diabetes mellitus patients, miRNA 223, miRNA 126, miRNA 197, miRNA 191, miRNA 21, miRNA 150, miRNA 155, miRNA 140, miRNA 96, miRNA 98 may be involved in the appearance of cardiovascular complications as reported recently[19]. miRNA alteration was also found in the background of primary immune thrombocytopenia[20]. Interestingly, not only may altered miRNA be responsible for the appearance of certain thrombotic illnesses, but also their own expression may be affected by surgical procedures, as was found in patients following cardiopulmonary bypass[21,22]. In these patients, overexpression of miRNAs 10b and 96 was found, and these changes resulted in a reduction in glycoprotein 1b and vesicle-associated membrane protein 8 at both the mRNA and protein level. This has been linked to impaired platelet function associated with the bypass surgery[22].

CONCLUSION

The available evidence in the literature points to an important role for miRNAs in platelet function, as well as in the regulation that platelets exert over surrounding cells. Further investigations of platelet miRNAs are required in order to fully understand the platelet signalling pathways that involve these molecules. Finally, it is possible that the production of anti-miRNAs (antagomirs) will become a promising research area for the prevention of thrombotic diseases.

Footnotes

Manuscript source: Invited Manuscript

Specialty type: Hematology

Country of origin: Spain

Peer-review report classification

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

P- Reviewer: Fukuda S, Schattner MA, Xavier-Elsas P S- Editor: Cui LJ L- Editor: A E- Editor: Song H

References
1.  Andreu D, Carreño C, Linde C, Boman HG, Andersson M. Identification of an anti-mycobacterial domain in NK-lysin and granulysin. Biochem J. 1999;344 Pt 3:845-849.  [PubMed]  [DOI]
2.  Hurley SM, Lutay N, Holmqvist B, Shannon O. The Dynamics of Platelet Activation during the Progression of Streptococcal Sepsis. PLoS One. 2016;11:e0163531.  [PubMed]  [DOI]
3.  Thon JN, Montalvo A, Patel-Hett S, Devine MT, Richardson JL, Ehrlicher A, Larson MK, Hoffmeister K, Hartwig JH, Italiano JE Jr. Cytoskeletal mechanics of proplatelet maturation and platelet release. J Cell Biol. 2010;191:861-874.  [PubMed]  [DOI]
4.  Rowley JW, Schwertz H, Weyrich AS. Platelet mRNA: the meaning behind the message. Curr Opin Hematol. 2012;19:385-391.  [PubMed]  [DOI]
5.  Kissopoulou A, Jonasson J, Lindahl TL, Osman A. Next generation sequencing analysis of human platelet PolyA+ mRNAs and rRNA-depleted total RNA. PLoS One. 2013;8:e81809.  [PubMed]  [DOI]
6.  Schubert S, Weyrich AS, Rowley JW. A tour through the transcriptional landscape of platelets. Blood. 2014;124:493-502.  [PubMed]  [DOI]
7.  Risitano A, Beaulieu LM, Vitseva O, Freedman JE. Platelets and platelet-like particles mediate intercellular RNA transfer. Blood. 2012;119:6288-6295.  [PubMed]  [DOI]
8.  Diehl P, Fricke A, Sander L, Stamm J, Bassler N, Htun N, Ziemann M, Helbing T, El-Osta A, Jowett JB. Microparticles: major transport vehicles for distinct microRNAs in circulation. Cardiovasc Res. 2012;93:633-644.  [PubMed]  [DOI]
9.  Xia L, Zeng Z, Tang WH. The Role of Platelet Microparticle Associated microRNAs in Cellular Crosstalk. Front Cardiovasc Med. 2018;5:29.  [PubMed]  [DOI]
10.  Ambrose AR, Alsahli MA, Kurmani SA, Goodall AH. Comparison of the release of microRNAs and extracellular vesicles from platelets in response to different agonists. Platelets. 2018;29:446-454.  [PubMed]  [DOI]
11.  Ambros V. Control of developmental timing in Caenorhabditis elegans. Curr Opin Genet Dev. 2000;10:428-433.  [PubMed]  [DOI]
12.  Rosado JA, Diez-Bello R, Salido GM, Jardin I. Fine-tuning of microRNAs in type 2 diabetes mellitus. Curr Med Chem. 2017;.  [PubMed]  [DOI]
13.  Qu M, Fang F, Zou X, Zeng Q, Fan Z, Chen L, Yue W, Xie X, Pei X. miR-125b modulates megakaryocyte maturation by targeting the cell-cycle inhibitor p19 INK4D. Cell Death Dis. 2016;7:e2430.  [PubMed]  [DOI]
14.  Emmrich S, Henke K, Hegermann J, Ochs M, Reinhardt D, Klusmann JH. miRNAs can increase the efficiency of ex vivo platelet generation. Ann Hematol. 2012;91:1673-1684.  [PubMed]  [DOI]
15.  Kaudewitz D, Skroblin P, Bender LH, Barwari T, Willeit P, Pechlaner R, Sunderland NP, Willeit K, Morton AC, Armstrong PC. Association of MicroRNAs and YRNAs With Platelet Function. Circ Res. 2016;118:420-432.  [PubMed]  [DOI]
16.  Dahiya N, Atreya CD. RAP1 Downregulation by miR-320c reduces Platelet Activation in Ex Vivo Storage. Microrna. 2018;.  [PubMed]  [DOI]
17.  Yan Y, Xie R, Zhang Q, Zhu X, Han J, Xia R. Bcl-xL/Bak interaction and regulation by miRNA let-7b in the intrinsic apoptotic pathway of stored platelets. Platelets. 2017;1-6.  [PubMed]  [DOI]
18.  Miao X, Rahman MF, Jiang L, Min Y, Tan S, Xie H, Lee L, Wang M, Malmström RE, Lui WO. Thrombin-reduced miR-27b attenuates platelet angiogenic activities in vitro via enhancing platelet synthesis of anti-angiogenic thrombospondin-1. J Thromb Haemost. 2018;16:791-801.  [PubMed]  [DOI]
19.  Zhao L, Wu S, Huang E, Gnatenko D, Bahou WF, Zhu W. Integrated micro/messenger RNA regulatory networks in essential thrombocytosis. PLoS One. 2018;13:e0191932.  [PubMed]  [DOI]
20.  Pordzik J, Pisarz K, De Rosa S, Jones AD, Eyileten C, Indolfi C, Malek L, Postula M. The Potential Role of Platelet-Related microRNAs in the Development of Cardiovascular Events in High-Risk Populations, Including Diabetic Patients: A Review. Front Endocrinol (Lausanne). 2018;9:74.  [PubMed]  [DOI]
21.  De Los Reyes-García AM, Arroyo AB, Teruel-Montoya R, Vicente V, Lozano ML, González-Conejero R, Martínez C. MicroRNAs as potential regulators of platelet function and bleeding diatheses. Platelets. 2018;1-6.  [PubMed]  [DOI]
22.  Mukai N, Nakayama Y, Ishi S, Ogawa S, Maeda S, Anada N, Murakami S, Mizobe T, Sawa T, Nakajima Y. Changes in MicroRNA Expression Level of Circulating Platelets Contribute to Platelet Defect After Cardiopulmonary Bypass. Crit Care Med. 2018;46:e761-e767.  [PubMed]  [DOI]